Kadmon Pharmaceuticals LLC
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$116Kgeneral payments (2019-2025)
$0.00research payments (2019-2025)
150clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Carlos Bachier | San Juan, PR | Hematology (Internal Medicine) | $8,636.13 |
| Amin Alousi | Houston, TX | Internal Medicine | $7,146.55 |
| Amandeep Salhotra | Duarte, CA | Hematology (Internal Medicine) | $6,983.88 |
| Parameswaran Hari | Milwaukee, WI | Hematology & Oncology | $6,117.71 |
| Iskra Pusic | Saint Louis, MO | Medical Oncology | $4,506.51 |
| Linda Perry | Philadelphia, PA | Medical | $4,120.96 |
| Doris Ponce | New York, NY | Hematology & Oncology | $4,037.96 |
| Bruce Blazar | Minneapolis, MN | Pediatric Hematology-Oncology | $3,610.00 |
| Zachariah Defilipp | Atlanta, GA | Hematology & Oncology | $3,492.35 |
| Corey Cutler | Boston, MA | Hematology & Oncology | $3,234.78 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.